Ardelyx faces shareholder class action over drug access and sales guidance
1 report, 1 independent
Updated Oct 15
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A class action lawsuit was filed against Ardelyx, Inc. on behalf of shareholders who purchased securities between January 13, 2025, and August 6, 2026. The complaint alleges that payer utilization-management barriers restricted patient access before the company reduced its 2026 guidance and withdrew its long-term XPHOZAH target.
From prnewswire.com
Why it matters
The lawsuit relates to previous sales projections, where Ardelyx pointed investors toward peak U.S. annual sales of $750 million for XPHOZAH and over $1 billion for IBSRELA. The complaint suggests these projections were undermined by access barriers, which preceded the company's guidance cuts.
Cost and access barriers limit patient care access.
From prnewswire.com